A Randomised, Double-blind, 8 Treatments, 4 Periods, Incomplete Crossover Study to Determine the Optimal Free Dose Combination of BI 1744 CL and Tiotropium Bromide (Both Delivered by the Respimat Inhaler) After 4 Weeks Once Daily Treatment in Patients With COPD.

Trial Profile

A Randomised, Double-blind, 8 Treatments, 4 Periods, Incomplete Crossover Study to Determine the Optimal Free Dose Combination of BI 1744 CL and Tiotropium Bromide (Both Delivered by the Respimat Inhaler) After 4 Weeks Once Daily Treatment in Patients With COPD.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Olodaterol (Primary) ; Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2015 Results published in the Advances in Therapy.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 03 Sep 2012 Results have been presented at the 2012 Annual Congress of the European Respiratory Society (ERS-2012) according to a Boehringer Ingelheim media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top